Novel anti-angiogenic therapies for malignant gliomas (Q37325086)

19 August 2017

1 reference

title

Novel anti-angiogenic therapies for malignant gliomas (English)

1 reference

19 August 2017

angiogenesis inhibitor

1 reference

3

Patrick Y Wen

1 reference

19 August 2017

Andrew D Norden

1

1 reference

PubMed ID

19007739

19 August 2017

Jan Drappatz

series ordinal

2

1 reference

19 August 2017

1 December 2008

1 reference

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

12

1 reference

19 August 2017

1152-1160

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Angiogenic inhibitors: a new therapeutic strategy in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

1 reference

7 January 2021

Angiogenesis in brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

1 reference

7 January 2021

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

The role of myeloid cells in the promotion of tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Cancer stem cells in radiation resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Making a tumour's bed: glioblastoma stem cells and the vascular niche.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Inhibition of angiogenesis and invasion in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Platelet-derived growth factor (PDGF) and glial tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Integrins in angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Medical management of brain tumor patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Reversible posterior leukoencephalopathy syndrome in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970260-6

7 January 2021

10.1016/S1474-4422(08)70260-6

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

19007739